References
- Solnick JU, Tompkins LS. Helicobacter pylori and gas-troduodenal disease: pathogenesis and host - parasite interac-tion. Infect Agents Dis 1983; 1: 294–309.
- Patel P, Mendall MA, Khulusi S, Northfield TC, Strachan DP. Helicobacter pylori infection in childhood: risk factors and effect on growth. Br Med J 1994; 309 (6962): 1119–23.
- Sauerbaum S, Wadstrom T. Bacterial pathogenic fac-tors. Curr Op Gastroenterol 1995; 11 (suppl 1): 11-5.
- Rappuoli R, Bugnoli M, Ghiara P, et al. Development of a vaccine against Helicobacter pylori: a short overview. Eur J Gastroenterol Hepatol 1993; 5 (suppl.2): 76-8.
- Katelaris P. Treatment of Helicobacter pylori infection. Biomed Pharmacother 1995; 49 (1): 5–10.
- Willems V, Janisch HD, Langmaack H. Omeprazole and ursodesoxycholic acid (UDCA) have selective activity against Helicobacter pylori. Irish J Med Sci 1992; 161 (suppl. 10).
- Midolo PD, Turnidge J, Lambert JR, Bell JM. Validation of a modified Kirby Bauer disk-diffusion method for metron-idazole susceptibility testing of Helicobacter pylori. Diagn Microbiol Infect Dis 1995; 21 (3): 135–40.
- Figura N, Armellini D, Bugnoli M, Bayeli PF, Gennari C, Crabtree JE. Activity of omeprazole on Helicobacter pylori and relation to toxicity of strains. J Clin Pathol 1994; 47 (5): 440–2.
- McGowan CC, Cover TL, Blaser MJ. The Proton Pump Inhibitor omeprazole inhibits acid survival of Helicobacter pylori by urease independent mechanism. Gastroenterology 1994; 107: 738–43.
- Belli WA, Fryklund J. Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori. Antimicrob Agents Chemother 1995; 39/8: 1717–20.
- Figura N, Armellini D, Bugnoli M, Bayeli PF, Gennari C, Crabtree JE. Activity of omeprazole on Helicobacter pylori and relation to toxicity of strains. J Clin Pathol 1994; 47 (5): 440–2.
- Lamouliatte H. Effect of lansoprazole on Helicobacter pylori. Clin Ther 1993; 15: 32–6.
- Rigner M, Aleljung P, Wadstrom T. Adherence of haemoagglutinating Helicobacter pylori to five cell lines. Int J Med Microbiol Virol Parasitol Infect Dis 1993; 280: 107–12.
- Piotrowsky J, Slomiany BL, VanHorn K, Sangupta S, Slomiany A. Sulfate mucins and sucralfate inhibit hemoaggluti-nation of erythrocytes by Campylobacter pylori. Gastroenterology 1990; 98: 107.
- Wagner S, Beil W, Mai UE, Bokemeyer C, Meyer HJ, Manns MP. Interaction between H. pylori and human gastric epithelial cells in culture: effects of antiulcer drugs. Pharmacology 1994; 49 (4): 226-37.
- Megraud F, Trimoulet P, Lamouliatte H, Boyanova L. Bactericidal effect of amoxicillin on Helicobacter pylori in an “in vitro” model using epithelial cells. Antimicrob Agents Chemother 1991; 35/5: 869–72.
- Gismondo MR, Drago L, Fassina C, Garlaschi ML, Rosina M, Lombardi A. E coli: Effect of fosfomycin trometa-mol on some urovirulence factors. J Chemother 1994; 6 (3): 167–72.
- Miller R. Pharmacokinetics and bioavailability of raniti-dine in humans. J Pharmacol Sci 1984; 73 (10): 1376–9.
- Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 1991; 21 (3): 178–94.
- Emody L, Carlsson A, Liungh A, Wadstrom T. Mannose resistant haemoagglutination by Camp ylobacter pylori. Scand J Infect Dis 1988; 20: 353–4.